Talon Therapeutics, Inc. announced that the Board has authorized a review of strategic alternatives. The Goldman Sachs Group, Inc. has been engaged to provide financial advisory services to Talon. The review of strategic alternatives may lead to a possible transaction, including the merger, business combination, or sale of Talon.

Talon does not plan to disclose or comment on developments regarding the strategic review process until further disclosure is deemed appropriate.